Royalty Pharma Plc (RPRX)vsSouthern Company (The) Series 2 (SOJE)
RPRX
Royalty Pharma Plc
$55.02
-0.76%
HEALTHCARE · Cap: $31.60B
SOJE
Southern Company (The) Series 2
$16.75
-0.18%
NONE · Cap: $65.72B
Smart Verdict
WallStSmart Research — data-driven comparison
RPRX leads profitability with a 33.9% profit margin vs 0.0%. RPRX earns a higher WallStSmart Score of 65/100 (C+).
RPRX
Buy65
out of 100
Grade: C+
SOJE
Avoid25
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-59.6%
Fair Value
$34.38
Current Price
$55.02
$20.64 premium
Intrinsic value data unavailable for SOJE.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 100.3%
Earnings expanding 23.2% YoY
Large-cap with strong market position
Areas to Watch
Expensive relative to growth rate
Moderate valuation
Elevated debt levels
Weak financial health signals
0.0% revenue growth
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : RPRX
The strongest argument for RPRX centers on Profit Margin, Operating Margin, EPS Growth. Profitability is solid with margins at 33.9% and operating margin at 100.3%. Revenue growth of 11.0% demonstrates continued momentum.
Bull Case : SOJE
The strongest argument for SOJE centers on Market Cap.
Bear Case : RPRX
The primary concerns for RPRX are PEG Ratio, P/E Ratio, Debt/Equity.
Bear Case : SOJE
The primary concerns for SOJE are Revenue Growth, EPS Growth, Profit Margin. Debt-to-equity of 2.05 is elevated, increasing financial risk.
Key Dynamics to Monitor
RPRX profiles as a mature stock while SOJE is a value play — different risk/reward profiles.
RPRX is growing revenue faster at 11.0% — sustainability is the question.
RPRX generates stronger free cash flow (761M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
RPRX scores higher overall (65/100 vs 25/100), backed by strong 33.9% margins and 11.0% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Royalty Pharma Plc
HEALTHCARE · BIOTECHNOLOGY · USA
Royalty Pharma plc is a buyer of biopharmaceutical royalties and funder of innovations in the biopharmaceutical industry in the United States. The company is headquartered in New York, New York.
Visit Website →Southern Company (The) Series 2
NONE · NONE · USA
Southern Company Series 2 is a leading player in the utility sector, focused on delivering reliable and sustainable energy solutions throughout the Southeastern United States. As a subsidiary of Southern Company, it enjoys a robust financial foundation and a diverse energy portfolio that includes natural gas, nuclear, and renewable sources. The company's commitment to innovation and environmental stewardship not only positions it advantageously for the ongoing energy transition but also makes it an attractive investment for institutional investors. Furthermore, its strong regulatory compliance and dedication to enhancing energy infrastructure empower Southern Company Series 2 to adeptly handle the dynamic challenges of the energy market.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?